A direct YBX1 inhibitor, SU056, has recently been shown to inhibit the cell proliferation of ovarian cancer cells by modulating YBX1-associated proteins and pathways, and the inhibition of YBX1 activity by SU056 treatment sensitizes ovarian cancer cells to palictaxel [34]. Here, YBX1 is linked to ovarian carcinoma.